Manatt Health July 25, 2023
Yelena Ofengeym, Anthony J. Fiori, Alexander Dworkowitz

Editor’s Note: In a new white paper, summarized below, Manatt Health discusses emerging reimbursement models for cell and gene therapies. The paper provides an overview of current Medicaid, Medicare and commercial coverage, including separate payment policies, value-based payment (VBP) arrangements and reinsurance programs. Click here to download a free copy of the full white paper.

More than ten cell and gene therapies have been approved by the FDA in the past five years,1 and over 500 gene-based therapies are in clinical development2 as of 2023. Based on current pipeline and product success rates, the Food and Drug Administration (FDA) anticipates approving 10–20 a year by 2025,3 with spending expected to reach $25 billion annually over the next ten years.4 With...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Insurance, Patient / Consumer, Payment Models, Pharma / Biotech, Provider, Value Based
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article